Healthcare

EBR Systems, Inc. (ASX:EBR) is a medical device company developing wireless cardiac pacing technology for people with heart failure who cannot receive conventional cardiac resynchronisation therapy (CRT). Its WiSE system delivers left ventricular endocardial pacing without a conventional pacing lead inside the left ventricle. …

EMVision Medical Devices Limited (ASX:EMV) develops portable brain imaging technology intended to bring neurological assessment closer to patients. Its emu bedside brain scanner and proposed first responder device address different care settings, from hospitals to ambulance transport. During 2026, the company reported clinical trial …

Psilocin is the active metabolite of psilocybin. With oral psilocybin, absorption and conversion within the body can vary between patients. An intravenous infusion delivers psilocin directly into circulation, allowing clinicians to adjust the administration rate. Entropy Neurodynamics (ASX:ENP) is investigating whether this can make …

EVE Health Group Limited (ASX:EVE) is an Australian life sciences company developing pharmaceutical formulations and drug-delivery technologies. Its 2026 activities have centred on the Libbo oral soluble film program, solubility research and work associated with its broader therapeutic portfolio. These projects illustrate the company’s …

Conventional CT examinations commonly capture anatomy without the patient placing weight on the affected joint. CurveBeam AI Limited (ASX:CVB) offers an alternative imaging configuration in which three-dimensional views can be obtained in a functional standing position. This may reveal differences in joint position, bone …

Technegas consists of ultra-fine carbon particles labelled with technetium-99m. After inhalation, the particles travel into the airways and lungs, allowing nuclear medicine cameras to map the distribution of inhaled gas. Clinicians can assess lung ventilation and compare it with blood-flow imaging when investigating conditions …

Cynata Therapeutics Limited (ASX:CYP) develops cell therapies using its proprietary Cymerus platform, which produces mesenchymal stromal cells (MSCs) from induced pluripotent stem cells (iPSCs). The manufacturing approach is designed to support consistent cell production without depending on a fresh tissue donation for every manufacturing …